IGHE and Eczematoid dermatitis: Previously, we have investigated the effects of pre- and postnatal ω-3 supplementation, demonstrating lower prevalence of sensitisation and IgE-associated eczema throughout the first year of life [17], and a decreased risk of developing any IgE-associated disease up to 2 years of age [18], in ω-3 compared to placebo-treated children.